Page 2 - Dr Reddy's Labs

A few bright spots for Dr Reddy's; stock is back on investors' radar

Stability in American business, new launches key as firm targets to double US portfolio in five years

Dr Reddy's enters $ 71 mn market with launch of anti-allergy drug in US

BS ReporterHyderabad, 16 March: Dr Reddy's Laboratories Limited announced today that it has launched Levocetrizine Dihydrochloride tablets, an over-the counter(OTC) therapeutic equivalent generic version of Xyzal Allergy tablets in the US market as approved by the US Food and Drug Administration(US FDA).The drug is an antihistamine used for 24-hour relief of allergy symptoms such as watery eyes, runny nose, itching eyes and nose and sneezing."This first-to-market launch for the store brand is the testament to the deep capabilities of our store brand OTC business,"said Milan Kalawadia, vice president and head, US OTC and Specialty Rx business at Dr Reddy's Laboratories. "We look forward to collaborating with our customers to bring high-quality, affordable store brand alternatives to the market."The Xyzal Allergy brand had US sales of approximately $ 71 million for the most recent twelve months ending in January 2018, according to the company. Xyzal is a registered trademark of UCB ...

Dr Reddy's gains 6% in two days post clarification on regulatory issues

The stock moved higher by 3% to Rs 2,473, extending its Thursday's 3% gain on BSE.

Dr Reddy's shines on favourable patent verdict

Launch of narcotic treatment drug may be sometime away, but it enhances earnings visibility

No immediate respite seen for Dr Reddy's

Even as not much was expected from Dr Reddy's March quarter results, the higher than estimated decline in profitability was a disappointment. With US FDA related issues remaining unresolved, the near-term outlook continues to be subdued. Revenues at Rs 3,554 crore for March quarter were down five per cent year-on-year, and came lower than Rs 3,683 crore estimated by analysts polled by Bloomberg. This was the fifth consecutive quarterly decline on a year-on-year basis, in revenues. Earnings before interest, tax, depreciation and amortisation (Ebitda) at Rs 630.3 crore was short by a bigger margin as compared to expectations of Rs 779 crore. Consequently, net profit at Rs 312.5 crore was significantly lower than estimates of Rs 385 crore. The major pressure point continues to be US sales. With the company's three Indian facilities under US FDA's warning letter, approvals for new product launches have been delayed thereby impacting the company's growth. Since US generic sales contribute .

USFDA completes inspection of Dr Reddy's Srikakulam SEZ unit

USFDA recently issued Form 483 with two observations to DRL's another API facility at Srikakulam

Dr Reddy's to market Integra's products in India

BS ReporterHyderabad, 27 March: Dr Reddy's Laboratories Limited and global medical technology company Integra LifeScinces Holdings Corporation announced today that they have entered into an exclusive distribution agreement under which the Hyderabad-based generic pharma major will market and distribute DuraGen Plus and Suturable DurgaGen dural regeneration matrices for use in patients in India.M V Ramana, executive vice president and head of emerging markets and India business at Dr Reddy's said,"We are delighted to partner with Integra LifeSciences. With the launch of DuraGen, we look forward to building our presence in the segment of regenerative technologies and making a difference to the lives of patients undergoing neurosurgery."Commenting on the tie-up, Integra LifeSciences chief financial officer Glenn Coleman stated that this collaboration will allow the company to expand patient access globally and provide innovative regenerative technology solutions to neurosurgeons and ...

Dr Reddy's Labs slumps 9% on weak Q1 earnings

Consolidated net profit was down 80% at Rs 126.3 core for the June quarter